Wafik S. El-Deiry: Daniel Arango on oncogenic mechanisms of NAT10
Wafik S. El-Deiry shared recent article by Daniel Arango, on X:
“Dr. Daniel Arango from Northwestern University and Lurie Cancer Center speaks about the oncogenic mechanisms of NAT10 as he delineates “the RNA acetylome.” NAT10 can also acetylate proteins.
Dr. Arango uses a variety of approaches including mutagenesis, PROTACs, and molecular modeling such as alpha fold to unravel functional domains.
Dr. Arango published a nice review about NAT10 in 2024 after previous publications in Cell on the mRNA modification.”
Tittle: Acetylation of Cytidine in mRNA Promotes Translation Efficiency
Authors: Daniel Arango, David Sturgill, Najwa Alhusaini, Allissa A. Dillman, Thomas J. Sweet, Gavin Hanson, Masaki Hosogane, Wilson R. Sinclair, Kyster K. Nanan, Mariana D. Mandler, Stephen D. Fox, Thomas T. Zengeya, Thorkell Andresson, Jordan L. Meier, Jeffery Coller and Shalini Oberdoerffer.
Wafik S. El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals. He is the Editor in Chief at Oncotarget. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023